gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · EDSAHealthcarePharmaceuticals

Edesa Biotech, Inc. Common Shares (EDSA)

$2.17−4.82%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$2.42▲ 39.08% in range
Nov 3, 2025Low $0.80 · High $18.27Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Edesa Biotech, Inc. Common Shares closed at $2.17 on Nov 4, down 4.82%, 88.1% below its 52-week closing high. Volume of 44.0K shares was 0.94× its 20-day average (close to normal).

Split-adjusted performance: -41.7% over one month, -85.5% over six months, +24.7% over one year.

Short interest was 161.3K shares at the Oct 15 settlement, down 20.8% from the prior report (2.3% of float, 3.5 days to cover).

Market cap$20.9M9.6M shares
Revenue · quarter$0.00—
Diluted EPS$-0.60—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range0.80 – 18.27−88.1% from high
Volume44.0K0.94× 20-day avg
Volatility · 60d88.7%Annualised
Short % of float2.3%3.5 days to cover
Net cash$10.3MCash $10.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −15.2%1M −41.7%3M −57.0%6M −85.5%YTD +52.8%1Y +24.7%3Y −31.1%5Y −96.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum4
Revenue growth—
Net margin—
Value (low P/E)—
Size22

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short161.3K−20.8% vs prior
Days to cover3.5Settled Oct 15
% of float2.3%
Short vol. 10d40.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
EDSAEdesa Biotech$2.17−4.82%−85.5%———$20.9M
AYTUAYTU BioPharma$1.92−0.52%−25.0%+6.4%−0.1%—$20.9MCompare
MCRBSeres Therapeutics$2.09+6.63%−73.9%—622.4%—$21.0MCompare
TXMDTherapeuticsMD$1.82+2.25%−10.3%−8.7%17.8%—$21.1MCompare
ATOSAtossa Therapeutics$2.12−9.01%−63.4%———$21.2MCompare
IGCIGC Pharma$0.1950+4.84%−38.7%−19.2%−1107.9%—$20.2MCompare
COCPCocrystal Pharma$1.01−5.61%−28.4%—−3013.3%—$19.5MCompare
CNTXContext Therapeutics$0.2035+4.90%−91.6%———$18.7MCompare
MIRAMIRA Pharmaceuticals$0.5610+8.34%−43.9%———$23.6MCompare

News about Edesa Biotech

All news →
Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsightGlobeNewswire Inc. · Jun 3, 2026▲ Positive

Quick answers

What does Edesa Biotech, Inc. Common Shares do?
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects.
What is EDSA's market cap?
$20.92M, based on the Nov 4 close of $2.17.
Does Edesa Biotech, Inc. Common Shares pay a dividend?
No regular cash dividend has been paid in the last year.
How much of EDSA is sold short?
161.3K shares, 2.3% of float, as of Oct 15, 2026.
What sector is EDSA in?
Healthcare, in the Pharmaceuticals industry.

About Edesa Biotech

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

HQ: Markham, 17 employeesListed Jun 9, 2010edesabiotech.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology